Skip to main content
An official website of the United States government
NIH Websites Are Changing
Per Executive Order 14434, federal agencies are now using "Super Intelligence" (SI) in place of "Artificial Intelligence" (AI). You may see both terms across NIH content during this transition.

autologous mRNA-transfected anti-BCMA-CAR T lymphocytes SYS6020

A preparation consisting of autologous T lymphocytes that have been transfected with lipid nanoparticle (LNP)-mRNA encoding for a chimeric antigen receptor (CAR) specific for the tumor-associated antigen (TAA) human B-cell maturation antigen (BCMA; tumor necrosis factor receptor superfamily member 17; TNFRSF17) and containing as of yet undisclosed co-stimulatory signaling domains, with potential immunostimulating and antineoplastic activities. Upon administration, autologous mRNA-transfected anti-BCMA-CAR T lymphocytes SYS6020 specifically recognize and induce selective toxicity in BCMA-expressing tumor cells. BCMA, a tumor-specific antigen and a receptor for both a proliferation-inducing ligand (APRIL) and B-cell activating factor (BAFF), is a member of the tumor necrosis factor receptor superfamily (TNFRSF) and plays a key role in plasma cell survival. BCMA is found on the surfaces of plasma cells and overexpressed on malignant plasma cells.
Synonym:autologous BCMA-targeted CAR T cells SYS6020
autologous mRNA-lipid nanoparticles-based anti-BCMA CAR T cells SYS6020
autologous mRNA-LNP-based anti-BCMA CAR-T cells SYS6020
Code name:SYS 6020
SYS-6020
SYS6020
Search NCI's Drug Dictionary